Skip to main content

Advertisement

SpringerLink
Log in

Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications

  • Immuno-oncology (RM Bukowski and JH Finke, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this review, we discuss modern cytokine delivery systems in oncologic care, focusing on modalities being developed in the clinical trials or currently in use. These include pegylation, immune-cytokine drug conjugates, cytokine-expressing plasmid nanoparticles, nonviral cytokine nanoparticles, viral systems, and AcTakines.

Recent Findings

Cytokine therapy has the potential to contribute to cancer treatment options by modulating the immune system towards an improved antitumor response and has shown promise both independently and in combination with other immunotherapy agents. Despite promising preliminary studies, systemic toxicities and challenges with administration have limited the impact of unmodified cytokine therapy. In the last decade, novel delivery systems have been developed to address these challenges and facilitate cytokine-based oncologic treatments.

Summary

Novel delivery systems provide potential solutions to decrease dose-limiting side effects, facilitate administration, and increase the therapeutic activity of cytokine treatments in oncology care. The expanding clinical and translational research in these systems provides an opportunity to augment the armamentarium of immune oncology and may represent the next frontier of cytokine-based immuno-oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

    Article  PubMed  Google Scholar 

  2. The Nobel Prize in Physiology or Medicine [press release]. The Nobel Assembly at Karolinska Institutet; 2018.

  3. Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125(9):3377–83.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Chen L, Han X. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest. 2015;125(9):3392–400.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37(S1):S34–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83(4):797–805.

    Article  CAS  PubMed  Google Scholar 

  8. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers. 2011;3(4).

  9. Lazarus HM, et al. Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time? Front Immunol. 2021. 12(3196).

  10. Abuchowski A, Van Es T, Palczuk N, Davis F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977;252(11):3578–81.

    Article  CAS  PubMed  Google Scholar 

  11. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®). Curr Pharm Des. 2004;10(11):1235–44.

    Article  CAS  PubMed  Google Scholar 

  12. • Mahler LJ, DiBlasi R, Perez A, Gaspard J, McCauley D. On-body injector: an administration device for pegfilgrastim. Clin J Oncol Nurs. 2017;21(1):121–2 Pegylation of cytokines allows delayed administration with decreased toxicity. The on-body injection device represents an innovative technology that facilitates convenient pegfilgrastim administration after chemotherapy administration.

    Article  PubMed  Google Scholar 

  13. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–26.

    Article  CAS  PubMed  Google Scholar 

  14. Bex A, Mallo H, Kerst M, Haanen J, Horenblas S. Gast GCd. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother. 2005;54(7):713–9.

    Article  CAS  PubMed  Google Scholar 

  15. • How J, Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers. 2020;12(7):1954 This review outlines the evolution in interferon-alfa pegylation facilitating its use in treatment for myeloproliferative neoplasms.

    Article  CAS  PubMed Central  Google Scholar 

  16. Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One. 2017;12(7):e0179431.

    Article  PubMed  PubMed Central  Google Scholar 

  17. •• Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol. 2016;34(29):3562 Phase Ib clinical trial demonstrating the potential of cytokine therapy (pegilodecakin, a pegylated IL-10) in combination with immune checkpoint blockade (pembrolizumab or nivolumab, anti-PD-1 agents.).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019;20(11):1544–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mishra P, Nayak B, Dey RK. PEGylation in anti-cancer therapy: an overview. Asian J Pharm Sci. 2016;11(3):337–48.

    Article  Google Scholar 

  20. • Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306 This preclinical trial used immunocytokine delivery to preferentially target certain immune cell populations and tumor tissues. Combination with immune checkpoint blockade exhibited synergy in preclinical models.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J ImmunoTher Cancer. 2019;7(1):240.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol. 1972;10(3):279–90.

    Article  CAS  PubMed  Google Scholar 

  23. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta. 1991;1088(1):131–4.

    Article  CAS  PubMed  Google Scholar 

  24. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15.

    Article  CAS  PubMed  Google Scholar 

  25. Kelsall BL, Stüber E, Neurath M, Strober W. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann N Y Acad Sci. 1996;795:116–26.

    Article  CAS  PubMed  Google Scholar 

  26. Ibe S, Qin Z, Schüler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med. 2001;194(11):1549–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541–8.

    CAS  PubMed  Google Scholar 

  28. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002;5(6):668–75.

    Article  CAS  PubMed  Google Scholar 

  29. • Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020;31(4):532–40 This plasmid encoding IL-12 was well tolerated in patients with advanced melanoma and provoked objective response in a significant number of patients. However, immune tolerance limited its impact.

    Article  CAS  PubMed  Google Scholar 

  30. Weide B, Neri D, Elia G. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunol Immunother. 2017;66(5):647–56.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Fewell JG, Matar M, Slobodkin G, Han S-O, Rice J, Hovanes B, et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Control Release. 2005;109(1-3):288–98.

    Article  CAS  PubMed  Google Scholar 

  32. •• Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, et al. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;147(2):283–90 Phase I clinical trial combining plasmid encoding IL-12 with neoadjuvant chemotherapy, demonstrated high tolerability with no dose limiting toxicities and positive findings in the tumor micro-environment.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(28):3460–73.

    Article  PubMed  Google Scholar 

  34. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    Article  CAS  PubMed  Google Scholar 

  35. Thaker PH, Bradley WH, Leath CA, Gunderson Jackson C, Borys N, Anwer K, et al. GEN-1 in combination with neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: a phase I dose-escalation study. Clin Cancer Res. 2021:clincanres.0360.2021.

  36. Zhai YZ, Zhou Y, Ma L, Feng GH. Effects of cell-mediated immunity induced by intramuscular chitosan-pJME/ GM-CSF nano-DNA vaccine in BAlb/c mice. Bing Du Xue Bao. 2014;30(4):423–8.

    CAS  PubMed  Google Scholar 

  37. Xu Q, Guo L, Gu X, Zhang B, Hu X, Zhang J, et al. Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12. Biomaterials. 2012;33(15):3909–18.

    Article  CAS  PubMed  Google Scholar 

  38. Sabel MS, Su G, Griffith KA, Chang AE. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat. 2010;122(2):325–36.

    Article  CAS  PubMed  Google Scholar 

  39. Suzuki R, Namai E, Oda Y, Nishiie N, Otake S, Koshima R, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release. 2010;142(2):245–50.

    Article  CAS  PubMed  Google Scholar 

  40. Brzóska K, Grądzka I, Kruszewski M. Impact of silver, gold, and iron oxide nanoparticles on cellular response to tumor necrosis factor. Toxicol Appl Pharmacol. 2018;356:140–50.

    Article  PubMed  Google Scholar 

  41. Hara K, Shirasuna K, Usui F, Karasawa T, Mizushina Y, Kimura H, et al. Interferon-tau attenuates uptake of nanoparticles and secretion of interleukin-1β in macrophages. PLoS ONE. 2014;9(12):e113974.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Hu B, Du H-J, Yan G-P, Zhuo R-X, Wu Y, Fan C-L. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor. Drug Deliv. 2014;21(3):204–12.

    Article  CAS  PubMed  Google Scholar 

  43. Qiu Y, Su M, Liu L, Tang Y, Pan Y, Sun J. Clinical application of cytokines in cancer immunotherapy. Drug Des Devel Ther. 2021;15:2269–87.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Cifani N, Chronopoulou L, Pompili B, Di Martino A, Bordi F, Sennato S, et al. Improved stability and efficacy of chitosan/pDNA complexes for gene delivery. Biotechnol Lett. 2015;37(3):557–65.

    Article  CAS  PubMed  Google Scholar 

  45. Yan C, Jie L, Yongqi W, Weiming X, Juqun X, Yanbing D, et al. Delivery of human NKG2D-IL-15 fusion gene by chitosan nanoparticles to enhance antitumor immunity. Biochem Biophys Res Commun. 2015;463(3):336–43.

    Article  CAS  PubMed  Google Scholar 

  46. Tan L, Han S, Ding S, Xiao W, Ding Y, Qian L, et al. Chitosan nanoparticle-based delivery of fused NKG2D-IL-21 gene suppresses colon cancer growth in mice. Int J Nanomedicine. 2017;12:3095–107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater. 2012;11(10):895–905.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Libutti SK, Paciotti GF, Myer L, Haynes R, Gannon W, Walker M, et al. Results of a completed phase I clinical trial of CYT-6091: a pegylated colloidal gold-TNF nanomedicine. J Clin Oncol. 2009;27(15_suppl):3586.

    Article  Google Scholar 

  49. Powell AC, Paciotti GF, Libutti SK. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. In: Grobmyer SR, Moudgil BM, editors. Cancer nanotechnology: methods and protocols. Totowa: Humana Press; 2010. p. 375–84.

    Chapter  Google Scholar 

  50. • Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143-e Review of clinically relevant nanoparticle technology and future directions.

    Article  Google Scholar 

  51. Pol JG, Workenhe ST, Konda P, Gujar S, Kroemer G. Cytokines in oncolytic virotherapy. Cytokine Growth Factor Rev. 2020;56:4–27.

    Article  CAS  PubMed  Google Scholar 

  52. Cruz FM, Colbert JD, Merino E, Kriegsman BA, Rock KL. The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules. Annu Rev Immunol. 2017;35(1):149–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Pol JG, Rességuier J, Lichty BD. Oncolytic viruses: a step into cancer immunotherapy. Virus Adapt Treat. 2011;4(1):1–21.

    Google Scholar 

  54. Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J ImmunoTher Cancer. 2016;4(1).

  55. Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, et al. Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus. Mol Ther Oncol. 2018;11:109–21.

    Article  CAS  Google Scholar 

  56. Kuryk L, Møller A-SW, Jaderberg M. Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. J Med Virol. 2019;91(9):1702–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. •• Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med. 2021;384(17):1613–22 Modified HSV-1 oncolytic virus showed changes in the tumor micro-environment via increase tumor infiltrating lymphocytes and improved patient overall survival.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. •• Gonzalez-Pastor R, Goedegebuure PS, Curiel DT. Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer. Cancer Gene Ther. 2021;28(5):375–89 Review of the adenovirus oncolytic virus system, including its potential role in combination with immune checkpoint inhibition or CAR-T therapy.

    Article  CAS  PubMed  Google Scholar 

  59. Eckert EC, Nace RA, Tonne JM, Evgin L, Vile RG, Russell SJ. Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9. Mol Ther Oncol. 2020;16:63–74.

    Article  CAS  Google Scholar 

  60. Liu Z, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL. CXCL11-armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. OncoImmunology. 2016;5(3):e1091554.

    Article  PubMed  Google Scholar 

  61. Francis L, Sheng Guo Z, Liu Z, Ravindranathan R, Urban JA, Sathaiah M, et al. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget. 2016;7(16).

  62. Pelosci A. FDA grants Fast Track Designation to ONCOS-102 for treatment of advanced melanoma: Cancer Network; 2021 [Available from: https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-oncos-102-for-treatment-of-advanced-melanoma.

  63. Greig SL. Talimogene laherparepvec: first global approval. Drugs. 2016;76(1):147–54.

    Article  CAS  PubMed  Google Scholar 

  64. Raman SS, Hecht JR, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019;11(8):705–23.

    Article  CAS  PubMed  Google Scholar 

  65. • Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, et al. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020;157(3):578–84 Phase I/II trial combining chemotherapy and transgene-delivering adenovirus to disrupt the tumor micro-environment in recurrent ovarian cancer.

    Article  CAS  PubMed  Google Scholar 

  66. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.

    Article  CAS  PubMed  Google Scholar 

  67. Huyghe L, Van Parys A, Cauwels A, Van Lint S, De Munter S, Bultinck J, et al. Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO Mol Med. 2020;12(2):e11223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Cauwels A, Tavernier J. Tolerizing strategies for the treatment of autoimmune diseases: from ex vivo to in vivo strategies. Front Immunol. 2020;11(674).

Download references

Funding

CAL was supported in part by the UG1 CA23330 and P50 CA098252.

Author information

Authors and Affiliations

  1. Department of Obstetrics & Gynecology, University of Alabama Division of Gynecologic Oncology, 1700 6th Avenue South, Room 10250, Birmingham, AL, 35249-7333, USA

    Jhalak Dholakia, Charles A. Leath III & Elizabeth T. Evans

  2. Department of Obstetrics & Gynecology, Washington University in St. Louis Division of Gynecologic Oncology, St. Louis, MO, USA

    Alexander C. Cohen & Premal H. Thaker

  3. Department of Obstetrics & Gynecology, Vanderbilt University Division of Gynecologic Oncology, Nashville, TN, USA

    Ronald D. Alvarez

Authors
  1. Jhalak Dholakia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander C. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles A. Leath III
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth T. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ronald D. Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Premal H. Thaker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jhalak Dholakia.

Ethics declarations

Conflict of Interest

Jhalak Dholakia declares that she has no conflict of interest. Alexander C. Cohen declares that he has no conflict of interest. Charles A. Leath III declares that he has no conflict of interest. Elizabeth T. Evans declares that she has no conflict of interest. Ronald D. Alvarez declares that he has no conflict of interest. Premal H. Thaker has received research funding (paid to her institution) from Merck and GlaxoSmithKline; has received compensation for service as a consultant from Celsion; has received speaker’s honoraria from GlaxoSmithKline and AstraZeneca; has participated on Data Safety Monitoring or advisory boards for Iovance Biotherapeutics, Novocure, Celsion, Agenus, Eisai, GlaxoSmithKline, and Seagen; and owns stock/stock options in Celsion.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Immuno-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dholakia, J., Cohen, A.C., Leath, C.A. et al. Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications. Curr Oncol Rep 24, 389–397 (2022). https://doi.org/10.1007/s11912-022-01221-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-022-01221-3

Keywords

Search

Navigation